Patents by Inventor Masahiro Amakawa

Masahiro Amakawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9034906
    Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: May 19, 2015
    Assignees: Asahi Glass Company, Limited, Kaken Pharmaceutical Co., Ltd.
    Inventors: Takahiko Murata, Masahiro Amakawa, Shin Teradaira, Yasushi Matsumura, Katsuhiko Konishi
  • Publication number: 20150018401
    Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
    Type: Application
    Filed: September 26, 2014
    Publication date: January 15, 2015
    Inventors: Takahiko MURATA, Masahiro AMAKAWA, Shin TERADAIRA, Yasushi MATSUMURA, Katsuhiko KONISHI
  • Patent number: 8877787
    Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 4, 2014
    Assignees: Asahi Glass Company, Limited, Kaken Pharmaceutical Co., Ltd.
    Inventors: Takahiko Murata, Masahiro Amakawa, Shin Teradaira, Yasushi Matsumura, Katsuhiko Konishi
  • Publication number: 20140128441
    Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
    Type: Application
    Filed: January 9, 2014
    Publication date: May 8, 2014
    Applicants: Kaken Pharmaceutical Co., Ltd., Asahi Glass Company, Limited
    Inventors: Takahiko MURATA, Masahiro AMAKAWA, Shin TERADAIRA, Yasushi MATSUMURA, Katsuhiko KONISHI
  • Patent number: 8691857
    Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: April 8, 2014
    Assignees: Asahi Glass Company, Ltd., Kaken Pharmaceutical Co., Ltd.
    Inventors: Takahiko Murata, Masahiro Amakawa, Shin Teradaira, Yasushi Matsumura, Katsuhiko Konishi
  • Patent number: 8394844
    Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1 -4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: March 12, 2013
    Assignees: Asahi Glass Company, Limited, Kaken Pharmaceutical Co., Ltd.
    Inventors: Takahiko Murata, Masahiro Amakawa, Shin Teradaira, Yasushi Matsumura, Katsuhiko Konishi
  • Publication number: 20110098481
    Abstract: Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.
    Type: Application
    Filed: November 2, 2010
    Publication date: April 28, 2011
    Applicants: ASAHI GLASS COMPANY, LIMITED, KAKEN PHARMACEUTICAL CO., LTD.
    Inventors: Takahiko MURATA, Masahiro AMAKAWA, Shin TERADAIRA, Yasushi MATSUMURA, Katsuhiko KONISHI
  • Publication number: 20080249144
    Abstract: Not only acute or chronic interstitial pneumonia and plumonary fibrosis but also chronic obstructive plumonary diseases, such as plumonary emphysema and chronic bronchitis, can be effectively prevented or treated by inhalation administration to the lung tissue of 2-{N-[4-(4-chlorobenzenesulfonylamino)butyl]-N-{3-[(4-isopropyl 2-thiazolyl)methoxy]benzyl}}-sulfamoylbenzoic acid or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: July 21, 2005
    Publication date: October 9, 2008
    Applicant: KAKEN PHARMACEUITICAL CO., LTD.
    Inventors: Toshiaki Okuda, Shigeo Kurokawa, Takahiko Murata, Masahiro Amakawa, Tsutomu Nakamura
  • Patent number: 6849597
    Abstract: An agent for prevention or treatment of diseases involving degeneration or death of nerve cells, characterized by containing a growth hormone secretion promoting substance as an active ingredient, is provided.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: February 1, 2005
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Takahiko Murata, Tadashi Ohyama, Masahiro Amakawa, Keiko Fujita, Haruyoshi Ueo
  • Publication number: 20050014675
    Abstract: An agent for prevention or treatment of vascular disease and renal dysfunction that are accompanied by the migration of vascular smooth muscle cells and mesangial cells comprises as an active ingredient a growth-hormone secretion promoting substance receptor agonist that have a strong inhibitory action on the migration of vascular smooth muscle cells and mesangial cells. Using such an agent for prevention or treatment, one can suppress arteriosclerosis, recurrence of intimal thickening after angioplasty, and even glomerulosclerosis.
    Type: Application
    Filed: December 5, 2002
    Publication date: January 20, 2005
    Inventors: Masahiro Amakawa, Takahiko Murata
  • Publication number: 20030100494
    Abstract: An agent for prevention or treatment of diseases involving degeneration or death of nerve cells, characterized by containing a growth hormone secretion promoting substance as an active ingredient, is provided.
    Type: Application
    Filed: June 27, 2002
    Publication date: May 29, 2003
    Inventors: Takahiko Murata, Tadashi Ohyama, Masahiro Amakawa, Keiko Fujita, Haruyoshi Ueo
  • Patent number: 6046164
    Abstract: The present invention relates to a method for treating diseases of periodontal tissue by administering a basic fibroblast growth factor, by which the tissue injury is treated to induce regeneration, curing or new attachment.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: April 4, 2000
    Assignee: Kaken Pharmaceutical Co., Ltd.
    Inventors: Taiji Asano, Hajime Sugimoto, Akio Terashima, Yoshiko Nakano, Masahiro Amakawa, Katumasa Saga